18,000 type 2 diabetes patients study found Mounjaro (tirzepatide) outperformed Ozempic (semaglutide) in weight loss after one year, with 15.
A study published in JAMA Internal Medicine found that Eli Lilly's Mounjaro (tirzepatide) outperformed Novo Nordisk's Ozempic (semaglutide) in weight loss among 18,000 patients with type 2 diabetes. After one year, Mounjaro patients lost an average of 15.3% of their body weight, compared to 8.3% for Ozempic users. Mounjaro patients were also more likely to lose 10% or 15% of their initial weight during the first year on the medications.
July 08, 2024
4 Articles